Dialysate and Plasma Meropenem Concentrations in Continuous Intra-peritoneal Regimen during Peritoneal Dialysis-Related Peritonitis.

Not Applicable

Completed

• Conditions: Peritoneal Dialysis (PD) patients with PD related peritonitis; PD- related peritonitis; Intraperitoneal meropenem; IP meropenem continuous regimen

• Registration Number: TCTR20191121002
• Lead Sponsor: Routine to research unit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-01-31
• Study Start: 2019-11-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Diagnosis of PD related peritonits: 2/3 criteria of abdominal pain,PD fluid show WBC > 100 cells and PMN > 50% or posirtive PD culture
Has risk factors or culture positive for ESBL producing organism
stable hemodynamic condition

Exclusion Criteria

conjunction exit site or tunnel infection
Peritonitis from other known cause
Presence of systemic inflammatory response syndrome
concomitant antibiotic for other conditions
Known allergy to meropenem or carbapenems

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
level of plasma and dialysate meropenem in CAPD patients with peritonitis. blood sample at 0,1,2,4,12,24 hr. Dialysate sample at 0,0.5,1,4,6,12,18,24 hr hplc method

Secondary Outcome Measures

Name	Time	Method
Peritonitis treatment outcome at 5 and 14 days after treatment cure rate